Vanguard Asset Management
WVE icon

Vanguard Asset Management’s Wave Life Sciences WVE Stock Holding History

Vanguard Asset Management’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$604K Buy
103,995
+29,300
+39% +$194K ﹤0.01% 2117
2026
Q1 		$542K Buy
+74,695
New +$973K ﹤0.01% 2056

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GP
GSK plc London $602M AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $47.2M AUM 32.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Asset Management's WVE Position: Q2 2026 in Review

Vanguard Asset Management increased its Wave Life Sciences (WVE) stake by 39% in Q2 2026, buying an estimated $194K and bringing the position to 103,995 shares worth $604K. The position accounts for ﹤0.01% of the portfolio, ranked #2117.

Vanguard Asset Management first reported a position in WVE in Q1 2026 and has held it in 2 quarters since. 221 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • Vanguard Asset Management held 103,995 shares of Wave Life Sciences worth $604K as of Q2 2026.
  • Vanguard Asset Management bought 29,300 Wave Life Sciences shares in Q2 2026, an estimated $194K.
  • Wave Life Sciences made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2117 holding.
  • Vanguard Asset Management first reported a position in Wave Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 221 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.